Clinical Trial

Investigating the DNN Noise Reduction Feature in Phonak Hearing Aids Using Ecological Momentary Assessment

Terminated
View on ClinicalTrials.gov →
Why the trial stopped
Corrupted data
Summary
The goal of this interventional study is to evaluate the DNN Noise reduction feature of Phonak hearing aids in adults with moderate to moderate severe hearing loss. The main questions it aims to answer are: Do participants correctly identify significantly more words on the AZBio Sentence Test when using Phonak's DNN NR feature than when using Competitor device A in a lab setting? Do participants subjectively rate the speech clarity, ease of listening, and listening confidence higher when using Phonak's DNN feature than when using Competitor device A in both a lab setting and a real-world cafe setting? Do participants have an overall preference for the Phonak device over the Competitor device A in a real-world cafe setting? Participants will be fit with both the Phonak device and a Competitor device A in the lab. They will be given the AZBio Sentence test and repeat as many words as they can in a simulated noisy environment. Following the lab visit, participants will meet in a group with three other conversation partners in a real-world setting and asked to complete subjective questionnaires during the visit.
Protocol Amendment History 4 changes
critical Trial status changed: Enrolling by Invitation → Terminated 2026-05-30
critical Reason stopped changed: — → Corrupted data 2026-05-30
notable Primary completion moved earlier: 2026-06-05 -> 2026-04-19 2026-05-30
minor Completion moved earlier: 2026-06-05 -> 2026-04-19 2026-05-30
Trial Details
NCT Number NCT07526428
Lead Sponsor Sonova AG
Conditions Hearing Loss
Enrollment 21 participants
Start Date 2026-04-09
Primary Completion 2026-04-19 (estimated)
Study Completion 2026-04-19 (estimated)
Updated on ClinicalTrials.gov 2026-05-29